To elucidate the potential mechanism by which the combined treatment induces ferroptosis in lung cancer cells, we evaluated its effect on the Nrf2/HO-1/GPX4 antioxidant axis, considering that the decreased GSH is upstream of this pathway. The gene discussed is GPX4; the disease is lung carcinoma.